ALGS Stock Overview
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aligos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.79 |
| 52 Week High | US$1.38 |
| 52 Week Low | US$0.54 |
| Beta | 2.34 |
| 1 Month Change | -14.87% |
| 3 Month Change | 16.80% |
| 1 Year Change | -27.90% |
| 3 Year Change | -96.95% |
| 5 Year Change | n/a |
| Change since IPO | -94.66% |
Recent News & Updates
Recent updates
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Apr 09
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues
Feb 23Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 24We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Jul 17We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Mar 11Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B
Jul 25We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Jul 11We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Feb 02Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 19Aligos Therapeutics EPS beats by $0.16
May 10We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely
May 01What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?
Jan 16Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study
Oct 30Shareholder Returns
| ALGS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -25.2% | -4.2% | -3.7% |
| 1Y | -27.9% | -2.0% | 20.5% |
Return vs Industry: ALGS underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: ALGS underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| ALGS volatility | |
|---|---|
| ALGS Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALGS's share price has been volatile over the past 3 months.
Volatility Over Time: ALGS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 66 | Larry Blatt | www.aligos.com |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.
Aligos Therapeutics, Inc. Fundamentals Summary
| ALGS fundamental statistics | |
|---|---|
| Market cap | US$59.55m |
| Earnings (TTM) | -US$87.68m |
| Revenue (TTM) | US$15.53m |
3.9x
P/S Ratio-0.7x
P/E RatioIs ALGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALGS income statement (TTM) | |
|---|---|
| Revenue | US$15.53m |
| Cost of Revenue | US$73.04m |
| Gross Profit | -US$57.51m |
| Other Expenses | US$30.17m |
| Earnings | -US$87.68m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | -370.35% |
| Net Profit Margin | -564.61% |
| Debt/Equity Ratio | 0% |
How did ALGS perform over the long term?
See historical performance and comparison